Results 41 to 50 of about 6,775 (167)

Exceptional Response to Fixed Duration Obinutuzumab and Venetoclax in a Patient with Chronic Lymphocytic Leukemia: A Case Report

Case Reports in Oncology
Introduction: Obinutuzumab is a standard treatment for chronic lymphocytic leukemia (CLL) in combination with venetoclax, following the CLL-14 trial.
Maya Rosenberg, Catherine Diefenbach
doaj   +1 more source

Single‐Cell Level Characterization of B Cell Depletion and Repopulation Following Rituximab in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang, Norzawani Buang, Catherine Sutherland, Wanseon Lee, Lauren Overend, Tarran S. Rupall, Katie L. Burnham, Matthew C. Pickering, Marina Botto, Emma E. Davenport   +9 more
wiley   +1 more source

Update on obinutuzumab in the treatment of B-cell malignancies. [PDF]

, 2014
INTRODUCTION: The anti-CD20 mAb rituximab has revolutionized the treatment of B-cell malignancies, improving outcome for patients. Despite these improvements, the majority of patients still relapse and become refractory to rituximab.
Jamie Honeychurch, Donaghy, Claire, Tim Illidge, Cheadle, Eleanor J, Claire Donaghy, Honeychurch, Jamie, Eleanor J Cheadle, Illidge, Tim; id_orcid   +7 more
core   +1 more source

Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis [PDF]

, 2022
OBJECTIVE: To assess time- and cost-savings in relation to active time of health care professional (HCP) and resource consumption of administering obinutuzumab as a short duration infusion (SDI) in patients in treatment for Follicular Lymphoma (FL ...
Pradelli, Lorenzo, Guardalben, Emanuele, Ghislieri, Daniela, Bellone, Marco, Tavarozzi, Rita, Nepoti, Giuliana, Ladetto, Marco   +6 more
core   +2 more sources

Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation

Frontiers in Drug Safety and Regulation, 2023
Introduction: In December 2020, the Italian Medicines Agency (AIFA) in collaboration with the Italian Regional Centers of Pharmacovigilance evaluated four individual case safety reports (ICSRs) reporting obinutuzumab and non-overt disseminated ...
Giulia Valdiserra, Nadia Mores, Rosalba Elisabetta Rocchi, Laura Sottosanti, Patrizia Felicetti, Pasquale Marchione, Luca Laurenti, Alberto Fresa, Giampaolo Bucaneve, Emiliano Cappello, Marco Bonaso, Sara Ferraro, Irma Convertino, Marco Tuccori, Marco Tuccori   +14 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. [PDF]

, 2014
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting ...
Goede, Valentin;Fischer, Kirsten;Busch, Raymonde;Engelke, Anja;Eichhorst, Barbara;Wendtner, Clemens M;Chagorova, Tatiana;de la Serna, Javier;Dilhuydy, Marie-Sarah;Illmer, Thomas;Opat, Stephen;Owen, Carolyn J;Samoylova, Olga;Kreuzer, Karl-Anton;Stilgenbauer, Stephan;Döhner, Hartmut;Langerak, Anton W;Ritgen, Matthias;Kneba, Michael;Asikanius, Elina;Humphrey, Kathryn;Wenger, Michael;Hallek, Michael
core   +3 more sources

Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study

Frontiers in Immunology
ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively ...
Xi Cheng, Zhen-feng Zheng, Yan Qi, Xin Cao, Xi-qian Gao, Ying-xin Fang, Li Wei, Wen-ya Shang, Tie-kun Yan, Jun-ya Jia, Peng-cheng Xu, Qiu-hua Gu   +11 more
doaj   +1 more source

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy [PDF]

, 2017
Othman Al-Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek, Valentin Goede German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany Abstract: For decades, treatment of chronic ...
Hallek M, Engelke A, Al-Sawaf O, Goede V, Fischer K, Pflug N   +5 more
core